NASDAQ · RLMD
Healthcare · Biotechnology
$3.48
Down-$0.20 (-5.75%)
Updated Oct 6, 2026, 11:28 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RLMD
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
RLMD closed at $3.48 after 20 trading sessions, down 18.12% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $3.60 | $3.70 | $3.415 | $3.48 | 1.28M |
| Oct 2, 2026 | $3.72 | $3.73 | $3.60 | $3.60 | 1.21M |
| Oct 1, 2026 | $3.73 | $3.80 | $3.65 | $3.66 | 1.36M |
| Sep 30, 2026 | $3.78 | $3.845 | $3.72 | $3.77 | 999.53K |
| Sep 29, 2026 | $3.82 | $3.89 | $3.695 | $3.73 | 863.55K |
| Sep 28, 2026 | $3.80 | $3.855 | $3.71 | $3.79 | 986.63K |
| Sep 25, 2026 | $3.81 | $3.87 | $3.73 | $3.83 | 1.31M |
| Sep 24, 2026 | $3.74 | $3.875 | $3.66 | $3.81 | 1.33M |
| Sep 23, 2026 | $4.26 | $4.26 | $3.77 | $3.78 | 1.13M |
| Sep 22, 2026 | $4.16 | $4.27 | $4.145 | $4.24 | 662.65K |
| Sep 21, 2026 | $4.13 | $4.235 | $4.075 | $4.16 | 552.73K |
| Sep 18, 2026 | $4.15 | $4.17 | $4.06 | $4.12 | 2.07M |
| Sep 17, 2026 | $4.28 | $4.39 | $4.18 | $4.20 | 772.91K |
| Sep 16, 2026 | $4.45 | $4.5724 | $4.205 | $4.22 | 824.38K |
| Sep 15, 2026 | $4.44 | $4.495 | $4.30 | $4.44 | 2M |
| Sep 14, 2026 | $4.52 | $4.56 | $4.42 | $4.44 | 1.26M |
| Sep 11, 2026 | $4.60 | $4.65 | $4.295 | $4.52 | 2.63M |
| Sep 10, 2026 | $4.25 | $4.25 | $4.00 | $4.07 | 2.81M |
| Sep 9, 2026 | $4.24 | $4.28 | $4.09 | $4.09 | 1.59M |
| Sep 8, 2026 | $4.40 | $4.425 | $4.13 | $4.25 | 1.7M |
The latest Smart Investors Daily articles mentioning RLMD.
Company
Market Activity
Research & News
RLMD research
Company profile and research snapshot.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 24, 2026 | Piper Sandler | Overweight | — |
| Mar 20, 2026 | Mizuho | Outperform | — |
| Mar 2, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jan 23, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Relmada Therapeutics is rated Hold as NVD-01 IND slips to 2026 despite strong NMIBC data; cash runway to 2029. Click here to read my latest analysis on RLMD stock.
Yahoo · Sep 1, 2026
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026. Wells Fargo 21st Annual Healthcare Conference DetailsFormat: One-o
Yahoo · Aug 31, 2026
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Yahoo · Aug 7, 2026
Relmada Therapeutics (NASDAQ:RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026. Chief
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLMD.
